Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025
SAN FRANCISCO and SUZHOU, China, May 6, 2025 /PRNewswire/ — Innovent Biologics,…